Today: 21 May 2026
Nebius Group (NBIS) stock falls as insider sale filings surface ahead of Jan. 2 trading restart
1 January 2026
2 mins read

Nebius Group (NBIS) stock falls as insider sale filings surface ahead of Jan. 2 trading restart

NEW YORK, December 31, 2025, 20:44 ET — Market closed

Nebius Group N.V. shares ended down 1.7% at $83.71 on Wednesday, after U.S. filings showed several insiders planned sales of the company’s Class A ordinary shares in early January. The stock traded between $82.94 and $86.41, with about 7.1 million shares changing hands.

The disclosure matters because Nebius has been a high-beta proxy for the AI infrastructure buildout, where sentiment can swing quickly on any sign of incremental supply. Investors in the group have also been focused on dilution risk and funding needs as the company ramps capacity.

Timing adds to the sensitivity. U.S. markets are closed on Thursday for New Year’s Day and reopen Friday, raising the odds that any orders tied to those planned sales could hit when liquidity is still rebuilding after the holiday.

A set of Form 144 notices — filings used to signal a proposed sale of securities under SEC Rule 144 — listed planned transactions largely scheduled for Jan. 2, 2026. Arkadiy Volozh proposed selling 41,000 shares (about $3.59 million using an indicative price), while Nave Ophir and Elena Bunina each proposed selling 2,300 shares (about $201,457 apiece) and Kira Radinsky proposed selling 500 shares (about $43,795), the filings showed.

Rule 144 governs the resale of restricted or “control” securities held by affiliates, and Form 144 is the notice that can accompany those sales. The filings are not proof a sale has happened, but they can flag potential near-term supply for the market to absorb. Thomson Reuters

The backdrop was risk-off year-end trading across U.S. equities. The S&P 500 fell 0.74% and the Nasdaq Composite slid 0.76% on Wednesday, with technology among the weakest sectors, according to Reuters. “It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity, pointing to profit-taking when liquidity is low. Reuters

Nebius, based in Amsterdam, is part of a crop of “neocloud” providers that rent out high-performance computing capacity, including Nvidia graphics processing units used to train and run AI models. The company has said demand for AI compute has been strong enough to create capacity constraints even for hyperscalers, and Reuters has previously cited CoreWeave as a larger rival in the same market. Reuters

The company has also tied its growth narrative to big-ticket customer contracts. In November, Nebius said it signed a roughly $3 billion agreement with Meta to provide AI infrastructure over five years, and Reuters has reported it previously struck a $17.4 billion deal with Microsoft.

Funding and capital intensity remain part of the equity story. Nebius said in September it would raise $3 billion — including a share offering and convertible notes — to fuel expansion, and Reuters reported the company emerged from a deal to split the assets of Russian tech firm Yandex.

With the stock closing near the lower end of Wednesday’s range, traders will be watching whether the $83 area holds when markets reopen. The mid-$80s zone is also in focus after the day’s high, with investors looking for signs that selling pressure is fading rather than building.

Before the next session, attention is likely to center on whether the proposed insider transactions show up in tape action on Jan. 2 and how quickly buyers step in. Because the filings described “sell-to-cover” transactions tied to compensation in several cases, investors will also parse whether the flow looks mechanical or broader. SEC

Beyond the immediate flow, the next scheduled checkpoints are operational and financial. Nasdaq’s earnings calendar lists Feb. 18, 2026 as an estimated reporting date, and investors will be listening for any update on spending and capacity plans that can move cash burn and dilution expectations.

Nebius has said in a prior SEC filing that GPU services under its Meta agreement would be deployed in two tranches during December 2025 and February 2026, putting execution on delivery timelines back on the near-term watch list as 2026 begins.

Stock Market Today

  • Coca-Cola and Beverage Sector Show Mixed Q1 Performance with Vita Coco Leading Gains
    May 20, 2026, 9:22 PM EDT. As Q1 earnings wrap up, beverages, alcohol, and tobacco stocks report mixed results. The sector beat revenue estimates by 4.9%, though next-quarter guidance fell short by 0.6%. Coca-Cola (NYSE:KO) posted strong growth with $12.47 billion in revenue, exceeding estimates by 2.5%, and shares rose 7.7%. Leading the pack was Vita Coco (NASDAQ:COCO), with a 37.3% revenue surge and a 54.1% stock gain post-earnings. In contrast, Boston Beer (NYSE:SAM) saw a 4.4% revenue decline and missed on operating income forecasts, marking the weakest performance among peers. Shifting consumer trends and social media-driven lower brand launch costs are reshaping competition in the sector.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious
Previous Story

AI stocks today: Nvidia, AMD tick higher as year-end trade turns cautious

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop